Glycemic Control Financial Incentive for Diabetes Mellitus, Type 2

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Medical College of Wisconsin, Milwaukee, WI
Diabetes Mellitus, Type 2+1 More
Glycemic Control Financial Incentive - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test if financial incentives can help improve HbA1c, blood pressure, and quality of life in food insecure adults with type 2 diabetes. The Glycemic Control Financial Incentive is being used to treat Diabetes Mellitus, Type 2. This is a condition where the body does not produce enough insulin, or the cells do not respond properly to insulin. This can lead to high blood sugar levels. The Glycemic Control Financial Incentive has been previously approved by the FDA for a different condition. However, this is the first time that it has been tested on patients with Diabetes Mellitus, Type 2. No patients in this trial will receive a placebo.

Eligible Conditions

  • Diabetes Mellitus, Type 2

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Diabetes Mellitus, Type 2

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 6-months post randomization

6-months post randomization
Blood pressure (both systolic and diastolic)
Glycemic control (HbA1c)
Quality of life as measured by the Short Form Health Survey (SF-12)

Trial Safety

Safety Progress

1 of 3

Other trials for Diabetes Mellitus, Type 2

Trial Design

3 Treatment Groups

Monthly Unconditional Financial Incentive
1 of 3
Monthly Unconditional Plus Healthy Food Purchasing Plus Glycemic Control Financi...
1 of 3
Monthly Unconditional Plus Healthy Food Purchasing Financial Incentive
1 of 3
Experimental Treatment

150 Total Participants · 3 Treatment Groups

Primary Treatment: Glycemic Control Financial Incentive · No Placebo Group · N/A

Monthly Unconditional Financial IncentiveExperimental Group · 2 Interventions: Monthly Unconditional Financial Incentive, Diabetes Education · Intervention Types: Behavioral, Behavioral
Monthly Unconditional Plus Healthy Food Purchasing Plus Glycemic Control Financial IncentiveExperimental Group · 4 Interventions: Weekly Food Purchasing Financial Incentive, Monthly Unconditional Financial Incentive, Diabetes Education, Glycemic Control Financial Incentive · Intervention Types: Behavioral, Behavioral, Behavioral, Behavioral
Monthly Unconditional Plus Healthy Food Purchasing Financial IncentiveExperimental Group · 3 Interventions: Weekly Food Purchasing Financial Incentive, Monthly Unconditional Financial Incentive, Diabetes Education · Intervention Types: Behavioral, Behavioral, Behavioral
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Diabetes Education
2019
Completed Phase 3
~2550

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 6-months post randomization
Closest Location: Medical College of Wisconsin · Milwaukee, WI
Photo of medical college of wisconsin 1Photo of medical college of wisconsin 2Photo of medical college of wisconsin 3
2006First Recorded Clinical Trial
7 TrialsResearching Diabetes Mellitus, Type 2
564 CompletedClinical Trials

Who is running the clinical trial?

Medical College of WisconsinLead Sponsor
547 Previous Clinical Trials
1,150,435 Total Patients Enrolled
11 Trials studying Diabetes Mellitus, Type 2
551,332 Patients Enrolled for Diabetes Mellitus, Type 2
Rebekah J Walker, PhDPrincipal InvestigatorMedical College of Wisconsin
1 Previous Clinical Trials
300 Total Patients Enrolled
1 Trials studying Diabetes Mellitus, Type 2
300 Patients Enrolled for Diabetes Mellitus, Type 2

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You must be at least 21 years old to be screened.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.